Special characteristics of atherosclerosis in chronic renal failure

Clinical Nephrology

Volumn 60, Issue SUPPL.1, 2003, Pages

  Amann, Kerstin ^a   Tyralla, K ^a   Gross, M L ^b   Eifert, T ^a   Adamczak, M ^b   Ritz, E ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Atherosclerosis; Chronic renal failure; Coronary arterial sclerosis; Plaque calcification; Plaque morphology; Vascular calcification

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CALCIUM; ENDOTHELIN 1; PARATHYROID HORMONE; PHOSPHORUS; UREA;

ANGIOCARDIOGRAPHY; AORTA MEDIA; ARTERY; ARTERY CALCIFICATION; ARTERY INTIMA; ARTERY MEDIA; ARTERY WALL; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOPSY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ELASTIC FIBER; ELASTICITY; EXTRACELLULAR MATRIX; FATALITY; HEART INFARCTION; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY DISEASE; MEDICAL DOCUMENTATION; MICROMORPHOLOGY; MORTALITY; OXIDATIVE STRESS; POPULATION RESEARCH; PREVALENCE; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; THICKNESS; UREMIA;

ANIMALS; ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 0038721313     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Amann K, Törnig J, Buzello M et al 2002 Effect of antioxidant therapy with dl-alpha-tocopherol on cardiovascular structure in experimental renal failure. Kidney Int 62: 877-884
2. Ansari A, Kaupke CJ, Vaziri ND, Miller R, Barbari A 1993 Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis. Int J Artif Organs 16: 31-36
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK 1998 Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607-617
4. Boaz M, Smetana S, Weinstein T et al 2000 Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356: 1213-1218
5. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC 1996 Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27: 394-401
6. Bro S, Bentzon JF, Falk E, Nielsen LB, Olgaard K 2002 Chronic renal failure enhances aortic atherosclerosis in apolipoprotein-E deficient mice. Nephrol Dial Transpl 17 (Suppl 1): 46a
7. Brownlee M 2001 Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820
8. Brzosko S, Krauze-Brzosko K, de Gaetano G, Iacoviello L 2002 Asymmetrical dimethylarginine and risk of acute coronary events. Lancet 359: 1620
9. Buzello M, Törnig J, Faulhaber J, Ehmke H, Ritz E, Amann K (in press) The (apo) E knockout mouse - a model documenting accelerated atherosclerosis in uremia. J Am Soc Nephrol
10. Carluccio F, Siems W, Stefanelli G, Sommerburg O, Grune T, Riedel E, Hampl H 2002 Homocysteine in chronic renal failure in relation to renal anemia and to oxidative stress parameters 4-hydroxynonenal and malondialdehyde. Clin Nephrol 58 (Suppl 1): S26-S30
11. Churchill DN, Taylor DW, Cook RJ et al 1992 Canadian Hemodialysis Morbidity Study. Am J Kidney Dis 19: 214-234
12. Clyne N, Lins LE, Pehrsson SK 1986 Occurence and significance of heart disease in uraemia. An autopsy study. Scand J Urol Nephrol 20: 307-311
13. Dahlof B, Devereux RB, Kjeldsen SE et al 2002 Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 1004-1010
14. Demer LL, Tintut Y, Parhami F 2002 Novel mechanisms in accelerated vascular calcification in renal disease patients. Curr Opin Nephrol Hypertens 11: 437-443
15. Deppisch RM, Beck W, Goehl H, Ritz E 2001 Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int Suppl 78: S271-S277
16. Fliser D, Pacini G, Engelleiter R et al 1998 Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53: 1343-1347
17. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK 2001 Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138
18. Goodman WG, Goldin J, Kuizon BD et al 2000 Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483
19. Hampl H, Sternberg C, Berweck S, Lange D, Wrenz F, Pohle C, Riedel E, Gogoll L, Hennig L 2002 Regression of left ventricular hypertrophy in hemodialysis patients is possible. Clin Nephrol 58 (Suppl 1): S72-S96
20. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS 1995 Congestive heart failure in dialysis patients: prevalence, incidence, prognosis, and risk factors. Kidney Int 47: 884-890
21. Hasdan G, Benchetrit S, Rashid G, Green J, Bernheim J, Rathaus M 2002 Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int 61: 586-590
22. Ibels LS, Alfrey AC, Huffer WE, Croswell PW, Anderson JT, Weil R 3rd 1979 Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 66: 790-796
23. Ikram H, Lynn KL, Bailey RB, Little PJ 1983 Cardiovascular changes in chronic hemodialysis patients. Kidney Int 24: 371-376
24. Jono S, McKee MD, Murry CE et al 2000 Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: E10-E17
25. Jungers P, Joly D, Massy Z et al 1999 Sustained reduction of hyperhomocysteinemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant 14: 2903-2906
26. Kielstein JT, Boger RH, Bode-Boger SM et al 2002 Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13: 170-176
27. Kramer W, Wizemann V, Thormann J, Kindler M, Mueller K, Schlepper M 1986 Cardiac dysfunction in patients on maintenance hemodialysis. I. The importance of associated heart diseases in determining alterations of cardiac performance. Contrib Nephrol 52: 97-109
28. Kronenberg F, Kuen E, Ritz E et al 2000 Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11: 105-115
29. Kronenberg F, Kuen E, Ritz E et al 2002 Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. J Am Soc Nephrol 13: 461-469
30. Lindner A, Charra B, Sherrard DJ, Scribner BH 1974 Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697-701
31. Loree HM, Kamm RD, Stringfellow RG et al 1992 Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 71: 850-858
32. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E 1996 Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 11: 2449-2452
33. Moe SM, O'Neill KD, Duan D et al 2002 Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638-647
34. Mourad JJ, Pannier B, Blacher J et al 2001 Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int 59: 1834-1841
35. Muntzel M, Massy Z, Ruellan N et al 2002 Chronic renal failure increase oxidative stress and accelerates atherosclerosis in apolipoprotein-E knock-out mice. Nephrol Dial Transpl 17 (Suppl 1): 46a
36. Narang R, Ridout D, Nonis C, Kooner JS 1997 Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease. Int J Cardiol 60: 73-79
37. Niebauer J, Volk HD, Kemp M et al 1999 Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353: 1838-1842
38. Oh J, Wunsch R, Turzer M et al 2002 Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106: 100-105
39. Park L, Raman KG, Lee KJ et al 1998 Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 9: 1025-1031
40. Richardson PD, Davies MJ, Born GV 1989 Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 2: 941-944
41. Ridker PM, Hennekens CH, Buring JE, Rifai N 2000 C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843
42. Schieffer B, Schieffer E, Hilfiker-Kleiner D et al 2000 Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101: 1372-1378
43. Schwarz U, Buzello M, Ritz E et al 2000 Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218-223
44. Scribner BH, Buri R, Caner JE, Hegstrom R, Burnell JM 1960 The treatment of chronic uremia by means of intermittent hemodialysis: a preliminary report. Trans Am Soc Intern Organs 6: 114-122
45. Shoji T, Emoto M, Tabata T et al 2002 Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int 61: 2187-2192
46. Siems W, Quast S, Carluccio F, Wiswedel I, Hirsch D, Augustin W, Hampl H, Riehle M, Sommerburg O 2002 Oxidative stress in chronic renal failure as a cardiovascular risk factor. Clin Nephrol 58 (Suppl 1): S12-S19
47. Siems WG, Sommerburg O, Grune T 2000 Erythrocyte free radical and energy metabolism. Clin Nephrol 53 (Suppl 1): S9-S17
48. Stefanski A, Schmidt KG, Waldherr R, Ritz E 1996 Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 50: 1321-1326
49. Stenvinkel P, Heimburger O, Paultre F et al 1999 Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911
50. Tenaglia AN, Peters KGP, Sketch Jr MH, Annex BH 1998 Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J 135: 10-14
51. Torzewski J, Torzewski M, Bowyer DE et al 1998 C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18: 1386-1392
52. Touyz RM, Schiffrin EL 2001 Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 19: 1245-1254
53. Tvedegaard E, Kamstrup O 1980 The effect of chronic renal failure in rabbits on plasma lipids and the concentration of cholesterol, calcium and phosphate in the aortic wall. Proc Eur Dial Transplant Assoc 17: 240-246
54. Valkonen VP, Paiva H, Salonen JT et al 2001 Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358: 2127-2128
55. Vaziri ND, Oveisi F, Ding Y 1998 Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 53: 1748-1754
56. Wanner C, Krane V, Ruf G, März W, Ritz E 1999 Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl 71: S222-S226
57. Witko-Sarsat V, Friedlander M, Nguyen Khoa T et al 1998 Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161: 2524-2532
58. Yusuf S, Sleight P, Pogue J et al 2000 Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prev Eval Study Investigators. N Engl J Med 342: 145-153
59. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C 1999 Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658
60. Zoccali C, Bode-Boger S, Mallamaci F et al 2001 Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358: 2113-2117
61. Zoccali C, Benedetto FA, Maas R et al 2002 Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 13: 490-496